Virtual Reality for Motor and Cognitive Function in People With Parkinson's Disease
NCT07931040, Not applicable, Recruiting, Universidade Metodista de Piracicaba
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Virtual Reality for Motor and Cognitive Function in People With Parkinson's Disease | ClinicalTrials.gov |
| NCT number | NCT07931040 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 30 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Universidade Metodista de Piracicaba | ClinicalTrials.gov |
| Conditions | PARKINSON DIS | ClinicalTrials.gov |
| Interventions | Stationary Cycling, Stationary Cycling Combined with Virtual Reality | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Montreal Cognitive Assessment (MoCA) | At baseline (pre-intervention), 12 weeks (post-intervention), and 30 days after the post-intervention assessment (follow-up). | The Montreal Cognitive Assessment (MoCA) is a standardized screening tool used to assess global cognitive function. It evaluates multiple cognitive domains, including attention, concentration, executive functions, memory, language, visuospatial abilities, abstraction, calculation, and orientation. The total score ranges from 0 to 30 points, with higher scores indicating better cognitive performance and lower scores indicating poorer cognitive performance. An additional point is added for individuals with 12 or fewer years of formal education, according to the official scoring guidelines, provided that the maximum score does not exceed 30 points. The MoCA will be used to evaluate changes in cognitive performance throughout the study. | ClinicalTrials.gov |
| Secondary | Functional Gait Assessment (FGA) | At baseline (pre-intervention), 12 weeks (post-intervention), and 30 days after the post-intervention assessment (follow-up). | The Functional Gait Assessment (FGA) is a clinical tool used to assess dynamic balance and postural stability during walking under different conditions. It consists of 10 items, each scored on a 4-point ordinal scale ranging from 0 (severe impairment) to 3 (normal performance), with a total score ranging from 0 to 30 points. Higher scores indicate better gait performance and dynamic balance, whereas lower scores indicate greater impairment. The FGA will be used to assess changes in gait performance and dynamic balance over the study period. | ClinicalTrials.gov |
| Secondary | Baropodometric Assessment (Foot Pressure Analysis) | At baseline (pre-intervention), 12 weeks (post-intervention), and 30 days after the post-intervention assessment (follow-up). | Baropodometric assessment is a non-invasive, instrument-based method used to evaluate plantar pressure distribution and foot-ground interaction during standing and/or walking. It provides quantitative measurements of plantar pressure and load distribution between the feet, allowing the analysis of static and dynamic plantar pressure characteristics. The assessment does not produce a single standardized total score; instead, results are expressed through specific quantitative parameters, such as mean plantar pressure, peak plantar pressure, and pressure distribution across different foot regions. These measurements will be used to evaluate changes in plantar pressure distribution and postural control throughout the study period. | ClinicalTrials.gov |
| Secondary | Parkinson's Disease Questionnaire (PDQ-39) | At baseline (pre-intervention), 12 weeks (post-intervention), and 30 days after the post-intervention assessment (follow-up). | The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific quality-of-life questionnaire designed to assess the impact of Parkinson's disease on patients' daily lives. It consists of 39 items distributed across eight domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. Each item is scored on a 5-point ordinal scale ranging from 0 (never) to 4 (always or cannot do at all), reflecting the frequency of difficulties experienced during the previous month. Domain scores are converted to a scale ranging from 0 to 100, where 0 represents no problems and 100 represents the maximum level of problems. Higher scores indicate greater difficulties and poorer health-related quality of life, whereas lower scores indicate fewer difficulties and better health-related quality of life. The PDQ-39 will be used to assess changes in health-related quality of life throughout the study period. | ClinicalTrials.gov |
| Secondary | Unified Parkinson's Disease Rating Scale (UPDRS) | At baseline (pre-intervention), 12 weeks (post-intervention), and 30 days after the post-intervention assessment (follow-up). | The Unified Parkinson's Disease Rating Scale (UPDRS) is a standardized clinical scale used to assess the severity and progression of Parkinson's disease. It consists of four parts: Part I, Mentation, Behavior, and Mood (4 items; score range: 0-16); Part II, Activities of Daily Living (13 items; score range: 0-52); Part III, Motor Examination (14 items; score range: 0-56); and Part IV, Complications of Therapy (11 items; score range: 0-44). Each item is scored from 0 to 4, according to the original scale guidelines. The total score ranges from 0 to 168 points, with higher scores indicating greater disease severity and impairment, whereas lower scores indicate less severe symptoms and impairment. The UPDRS will be used to assess changes in the clinical manifestations of Parkinson's disease throughout the study period. | ClinicalTrials.gov |
| Secondary | Timed Up and Go (TUG) Test | At baseline (pre-intervention), 12 weeks (post-intervention), and 30 days after the post-intervention assessment (follow-up). | The Timed Up and Go (TUG) test is a clinical assessment tool used to evaluate functional mobility, dynamic balance, and gait performance. The test measures the time required for a participant to stand up from a chair, walk 3 meters at a comfortable and safe pace, turn around, walk back to the chair, and sit down again. The test is performed according to standardized procedures, and the completion time is recorded in seconds. The test does not have a standardized minimum or maximum score, as the outcome is expressed as completion time in seconds. Shorter completion times indicate better functional mobility and performance, whereas longer times indicate poorer functional mobility and potentially impaired dynamic balance. The TUG test will be used to assess changes in functional mobility throughout the study period. | ClinicalTrials.gov |
| Secondary | Freezing of Gait Questionnaire (FOG-Q) | At baseline (pre-intervention), 12 weeks (post-intervention), and 30 days after the post-intervention assessment (follow-up). | The Freezing of Gait Questionnaire (FOG-Q) is a disease-specific assessment tool used to evaluate the severity and impact of freezing of gait in individuals with Parkinson's disease. It consists of six items assessing the frequency and duration of freezing episodes, their impact on walking, and related gait difficulties. Each item is scored on a 5-point ordinal scale ranging from 0 to 4, with a total score ranging from 0 to 24 points. A score of 0 indicates the absence of freezing-related symptoms, whereas a score of 24 indicates the maximum severity. Higher scores indicate greater severity and impact of freezing of gait, while lower scores indicate less severe symptoms. The FOG-Q will be used to assess changes in freezing of gait symptoms throughout the study period. | ClinicalTrials.gov |
| Secondary | Six-Minute Walk Test (6MWT) | At baseline (pre-intervention), 12 weeks (post-intervention), and 30 days after the post-intervention assessment (follow-up). | The Six-Minute Walk Test (6MWT) is a standardized functional exercise test used to assess functional exercise capacity and walking endurance. Participants are instructed to walk for six minutes along a flat, standardized course, covering as much distance as possible at their own pace while maintaining a safe level of exertion. The total distance walked is measured in meters and recorded as the primary outcome of the test. The test does not have a standardized minimum or maximum score, as the outcome is expressed as the distance covered in meters. Greater distances indicate better functional exercise capacity and walking endurance, whereas shorter distances indicate poorer functional exercise capacity. The 6MWT will be used to assess changes in walking performance throughout the study period. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.